The Community Oncology Alliance got most of its 2016 Christmas list. CVS Caremark dropped its plan to cut physician-owned dispensaries out of Medicare Part D oral drug distribution, CMS eased off the gas pedal on the Medicare Access and CHIP Reauthorization Act, and the Medicare Part B Drug Payment Model has been discontinued for now.
Guru Sonpavde, MD, discusses challenges with sequencing in advanced renal cell carcinoma and his vision for the field going forward.
Cota, a New York-based precision informatics company, has developed what it says will be a significant aid for oncology practices working to conform to the expectations of CMS’s Oncology Care Model, which is designed to encourage physicians to strive for better patient outcomes and lower costs.
The FDA has granted a priority review to a supplemental new drug application for the use of the PD-L1 inhibitor atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma as a frontline therapy or following progression occurring ≥12 months after neoadjuvant or adjuvant chemotherapy.
The FDA has lifted its clinical hold on trials exploring pacritinib, according to CTI BioPharma, the developer of the JAK2/FLT3 inhibitor.
The FDA has granted a priority review to a supplemental new drug application for the use of regorafenib as a second-line treatment for patients with unresectable hepatocellular carcinoma.
Florida is a leader in the consolidation trend, topping the nation in the number of practices that have closed, merged, or been acquired in recent years.
Boston-based Berg Health is attempting to do away with a traditional form of scientific inquiry in an attempt to find better answers.
The FDA has placed clinical holds on several phase I trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia, according to Seattle Genetics, the manufacturer of the antibody-drug conjugate.